CEO, Biogen Idec
Total Compensation: $13.45 million
Professional Profile: George Scangos, 65, is one of the growing number of CEOs on our list who was a scientist first. He has a Ph.D. in microbiology and was a biology professor at Johns Hopkins University before he moved into the biotech business. He started in the industry at Bayer, where he eventually became president of Bayer Biotechnology. In 1996 he left to join Exelixis as president and CEO, and from there leapt to the CEO's post at Biogen Idec ($BIIB).
Compensation Breakdown: $1.294 million in salary, $7.96 million in stock, and $3.78 million in incentive pay, plus $38,787 in pension benefits and $377,530 in perks and other compensation.
Company Performance: Biogen had a good year last year. Its sales grew by 9% to $5.5 billion, and earnings took a double-digit leap. Two new drugs for multiple sclerosis moved along the late-stage timeline, and so did its hemophilia treatments, which could carve out a new niche for the company. And 2013 looks to be even better, with its now-approved MS drug, Tecfidera, already sweeping up impressive prescription numbers. Scangos can't take all the credit for the company's recent success; after all, he did inherit a company already stocked with key development programs when he took the helm in 2010. But he did make some tough decisions along the way, including early moves to pull the plug on oncology research and cut operations in San Diego. Biogen shares have soared 174% since he signed on there in 2010 and rose 32.5% during 2012.
Special Reports: George Scangos - The 25 most influential people in biopharma today | Biogen Idec - The Biggest R&D Spenders in Biotech
Biogen CEO Scangos scores 19% pay hike during stellar 2012
Biogen MS pill soars onstage with impressive first-week script numbers
Biogen's Tecfidera expected to hit the MS market running
Armed with diagnostic, Biogen files for first-line Tysabri use
Why George Scangos deserves credit for Biogen's hot streak
Biogen, Shire, Novo top pharma ranking of shareholder value
Biogen streak lives on with upbeat PhIII results for hemophilia A therapy